Evidence map›Paper›PMID 41346314›Full record

ReviewClinical pharmacology and therapeutics2026

Navigating the Genetic Risk of Chemotherapy-Induced Hearing Loss in the Stria Vascularis.

Tara Lazetic, Deanne Nixie R Miao, Britt I Drögemöller, Alain Dabdoub, Julia M Abitbol

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tara LazeticDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.ORCID 0009-0002-5780-2082
Deanne Nixie R MiaoDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0009-0008-5825-3074
Britt I DrögemöllerDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-3348-5855
Alain DabdoubDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-4259-2425
Julia M AbitbolBiological Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada.ORCID 0000-0002-4433-1923

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted. Growing evidence suggests certain genetic variants expressed in the SV are significant risk factors for ototoxicity, which may be leveraged to better understand cisplatin-induced hearing loss. Also highlighted are innovative developments in integrating genomic and transcriptomic data through multi-omic approaches that may be translated to improve future genetic testing and otoprotectant development.

Indexed as

Antineoplastic AgentsCisplatinHearing LossOtotoxicityStria VascularisAnimalsGenetic Predisposition to DiseaseGenetic TestingHumansRisk AssessmentRisk FactorsAntineoplastic AgentsCisplatin

Identifiers

PMID41346314
PMCPMC12997515

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.